A Multi-Site, Open-Label, Trial of the Efficacy and Safety of Fixed-dose Elbasvir/Grazoprevir (EBR/GZR) in Brazilian Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2017
Price : $35 *
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Fibrosis; Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Aug 2017 Planned initiation date changed from 29 Nov 2017 to 12 Feb 2018.
- 23 May 2017 Planned End Date changed from 13 Oct 2018 to 12 Jan 2019.